[1] Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity[J].Cell, 2006, 124(4):783-802.
[2] Kawai T,Akira S. The role of pattern-recognition receptors in innate immunity:update on Toll-like receptors[J].Nat Immunol, 2010, 11(5):373-384.
[3] Elinav E, Strowig T, Henao-Mejia J. Regulation of the antimicrobial response by NLR proteins[J].Immunity,2011, 34(5):665-679.
[4] Loo YM,Gale M. Immune signaling by RIG-I-like receptors[J].Immunity, 2011, 34(5):680-692.
[5] Osorio F,Reis-e-Sousa C. Myeloid C-type lectin receptors in pathogen recognition and host defense[J].Immunity, 2011, 34(5):651-664.
[6] Adachi K, Tsutsui H, Kashiwamura S. Plasmodium berghei infection in mice induces liver injury by an IL-12-and Toll-like receptor/myeloid differentiation factor 88-dependent mechanism[J].J Immunol, 2001, 167(10):5928-5934.
[7] Beutler BA. TLRs and innate immunity[J].Blood, 2009, 113(7):1399-1407.
[8] Blasius AL,Beutler B. Intracellular toll-like receptors[J].Immunity, 2010, 32(3):305-315.
[9] Pifer R, Benson A, Sturge CR. UNC93B1 is essential for TLR11 activation and IL-12-dependent host resistance to Toxoplasma gondii[J].J Bio Chem, 2011, 286(5):3307-3314.
[10] Kobayashi K, Hernandez LD, Galan JE. IRAK-M is a negative regulator of Toll-like receptor signaling[J].Cell, 2002,110(2):191-202.
[11] Barton GM,Kagan JC. A cell biological view of Toll-like receptor function:regulation through compartmentalization[J].Nat Rev Immunol, 2009, 9(8):535-542.
[12] Sasai M, Linehan MM, Iwasaki A. Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3[J].Science, 2010, 329(5998):1530-1534.
[13] Haas T, Metzger J, Schmitz F. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation[J].Immunity, 2008, 28(3):315-323.
[14] Park B, Buti L, Matsuwaki T. Granulin is a soluble cofactor for toll-like receptor 9 signaling[J].Immunity, 2011, 34(4):505-513.
[15] Mancuso G, Gambuzza M, Midiri A. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells[J].Nat immunol, 2009, 10(6):587-594.
[16] Miao EA, Andersen-Nissen E, Warren SE. TLR5 and Ipaf:dual sensors of bacterial flagellin in the innate immune system[J].Semin Immunopathol, 2007, 29(3):275-288.
[17] Gerold G, Zychlinsky A,de Diego JL. What is the role of Toll-like receptors in bacterial infections[J].Semin Immunol, 2007, 19(1):41-47.
[18] Weiss DS, Raupach B, Takeda K. Toll-like receptors are temporally involved in host defense[J].J Immunol,2004, 172(7):4463-4469.
[19] Feuillet V, Medjane S, Mondor I. Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria[J].Proc Natl Acad of Sci, 2006, 103(33):12487-12492.
[20] Saiga H, Shimada Y, Takeda K. Innate immune effectors in mycobacterial infection[J].Clin Develop Immunol, 2011, 2011:347594.
[21] H lscher C, Reiling N, Schaible UE. Containment of aerogenic Mycobacterium tuberculosis infection in mice does not require MyD88 adaptor function for TLR2,4 and9 [J].Eur J Immunol,2008, 38(3):680-694.
[22] Gandotra S, Jang S, Murray PJ. Nucleotide-binding oligomerization domain protein 2-deficient mice control infection with Mycobacterium tuberculosis[J].Infect Immun,2007, 75(11):5127-5134.
[23] Dorhoi A, Desel C, Yeremeev V. The adaptor molecule CARD9 is essential for tuberculosis control[J].J Exp Med, 2010, 207(4):777-792.
[24] Reizis B, Bunin A, Ghosh HS. Plasmacytoid dendritic cells:recent progress and open questions[J].Annu Rev Immunol, 2011, 29:163-183.
[25] Lee HK, Lund JM, Ramanathan B. Autophagy-dependent viral recognition by plasmacytoid dendritic cells[J].Science,2007, 315(5817):1398-1401.
[26] Kumagai Y, Takeuchi O, Kato H. Alveolar macrophages are the primary interferon-α producer in pulmonary infection with RNA viruses[J].Immunity, 2007, 27(2):240-252.
[27] Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus[J].J Biol Chem, 2010, 285(30):22741-22747.
[28] Shiina M, Rehermann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function[J].Hepatology,2008, 47(2):385-395.
[29] Jasani B, Navabi H, Adams M. Ampligen:a potential toll-like 3 receptor adjuvant for immunotherapy of cancer[J].Vaccine, 2009, 27(25):3401-3404.
[30] Navabi H, Jassni B, Reece A. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro[J].Vaccine, 2009, 27(1):107-115.
[31] Krieg AM. Toll-free vaccines[J].Nat Biotechnol, 2007, 25(3):303-305.
[32] Huleatt JW, Nakaar V, Desai P. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin[J].Vaccine,2008, 26(2):201-214.
[33] Kronenberger B,Zeuzem S. Current and future treatment options for HCV[J].Ann Hepatol,2009, 8(2):103-112.
[34] Agrawal S,Kandimalla ER. Synthetic agonists of Toll-like receptors 7, 8 and 9[J].Biochem Soc Trans, 2007, 35(Pt 6):1461-1467.
[35] Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy[J].Expert Opin Biol Ther, 2007, 7(11):1731-1737.
[36] Rice TW, Wheeler AP, Bernard GR. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis[J].Crit Care Med, 2010, 38(8):1685-1694.
[37] Ledeboer A, Liu T, Shumilla JA. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain[J].Neuron Glia Biol, 2006, 2(4):279-291.
[38] Ledeboer A, Hutchinson MR, Watkins LR. Ibudilast (AV-411) a new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes[J].Expert Opin Invest Drugs, 2007, 16(7):935-950.
[39] Urbonaviciute V, Furnrohr,BF, Meister S. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes:implications for the pathogenesis of SLE[J].J Exp Med, 2008, 205(13):3007-3018.
[40] Arslan F, de Kleijn DP, Timmers L. Bridging innate immunity and myocardial ischemia/reperfusion injury:the search for therapeutic targets[J].Curr Pharm Des, 2008, 14(12):1205-1216.
[41] Sun S, Rao NL, Venable J. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders[J]. Inflamm Allergy Drug Targets, 2007, 6(4):223-235.
[42] Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors:emerging therapeutics[J].Nat Rev Drug Discov, 2010, 9(4):293-307.